Advertisement
Canada markets close in 5 hours 39 minutes

  • S&P/TSX

    21,947.30
    +61.92 (+0.28%)
     

  • S&P 500

    5,100.81
    +52.39 (+1.04%)
     

  • DOW

    38,261.43
    +175.63 (+0.46%)
     

  • CAD/USD

    0.7318
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    83.94
    +0.37 (+0.44%)
     

  • Bitcoin CAD

    88,400.87
    +1,331.14 (+1.53%)
     

  • CMC Crypto 200

    1,338.36
    -58.17 (-4.16%)
     

  • GOLD FUTURES

    2,351.10
    +8.60 (+0.37%)
     

  • RUSSELL 2000

    2,000.25
    +19.13 (+0.97%)
     

  • 10-Yr Bond

    4.6590
    -0.0470 (-1.00%)
     

  • NASDAQ

    15,903.70
    +291.94 (+1.87%)
     

  • VOLATILITY

    15.35
    -0.02 (-0.13%)
     

  • FTSE

    8,132.42
    +53.56 (+0.66%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6840
    +0.0019 (+0.28%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Investor Insights: Teva Pharmaceutical’s Valuation Multiples

Sarah Collins
Updated
Investor Insights: Teva Pharmaceutical’s Valuation Multiples

On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.

Continue reading